Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region

<strong>Background</strong>: Zika virus (ZIKV) has become a global threat with immediate need for accurate diagnostics, efficacious vaccines and therapeutics. Several ZIKV envelope (Env)-based vaccines have been developed recently. However, many commercially available ZIKV Env are based...

Full description

Bibliographic Details
Main Authors: Kim, Y, Lopez-Camacho, C, Nettleship, J, Rahman, N, Hill, M, Silva-Reyes, L, Ortiz-Martinez, G, Figueroa-Aguilar, G, Mar, M, Vivanco-Cid, H, Rollier, C, Zitzmann, N, Viveros-Sandoval, M, Owens, R, Reyes-Sandoval, A
Format: Journal article
Published: BioMed Central 2018
_version_ 1797071844244717568
author Kim, Y
Lopez-Camacho, C
Nettleship, J
Rahman, N
Hill, M
Silva-Reyes, L
Ortiz-Martinez, G
Figueroa-Aguilar, G
Mar, M
Vivanco-Cid, H
Rollier, C
Zitzmann, N
Viveros-Sandoval, M
Owens, R
Reyes-Sandoval, A
author_facet Kim, Y
Lopez-Camacho, C
Nettleship, J
Rahman, N
Hill, M
Silva-Reyes, L
Ortiz-Martinez, G
Figueroa-Aguilar, G
Mar, M
Vivanco-Cid, H
Rollier, C
Zitzmann, N
Viveros-Sandoval, M
Owens, R
Reyes-Sandoval, A
author_sort Kim, Y
collection OXFORD
description <strong>Background</strong>: Zika virus (ZIKV) has become a global threat with immediate need for accurate diagnostics, efficacious vaccines and therapeutics. Several ZIKV envelope (Env)-based vaccines have been developed recently. However, many commercially available ZIKV Env are based on the African lineage and produced in insect cells. Here, we sought to produce Asian-lineage ZIKV Env in mammalian cells for research and clinical applications. <strong>Methods</strong>: We designed various gene expression constructs to optimize the production of ZIKV using prM-Env and full or C-terminal truncations of Env; with or without a rat CD4 fusion partner to allow large-scale production of soluble protein in mammalian HEK293 cells. Protein expression was verified by mass spectrometry and western-blot with a pan-flavivirus antibody, a ZIKV Env monoclonal antibody and with immune sera from adenoviral (ChAdOx1) ZIKV Env-vaccinated mice. The resulting Env-CD4 was used as a coating reagent for immunoassay (ELISA) using both mouse and human seropositive sera. <strong>Results</strong>: Replacement of the C-terminus transmembrane Env domain by a rat CD4 and addition of prM supported optimal expression and secretion of Env. Binding between the antigens and the antibodies was similar to binding when using commercially available ZIKV Env reagents. Furthermore, antibodies from ZIKV patients bound ZIKV Env-CD4 in ELISA assays, whereas sera from healthy blood donors yielded minimal OD background. The serological outcomes of this assay correlated also with ZIKV neutralisation capacity in vitro. <strong>Conclusions</strong>: Results obtained from this study indicate the potential of the Asian-lineage Zika Env-CD4 and Env proteins in ELISA assays to monitor humoral immune responses in upcoming clinical trials as well as a sero-diagnostic tool in ZIKV infection.
first_indexed 2024-03-06T22:59:06Z
format Journal article
id oxford-uuid:617364e6-8063-4807-8739-d295a0d4e888
institution University of Oxford
last_indexed 2024-03-06T22:59:06Z
publishDate 2018
publisher BioMed Central
record_format dspace
spelling oxford-uuid:617364e6-8063-4807-8739-d295a0d4e8882022-03-26T18:00:07ZOptimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic regionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:617364e6-8063-4807-8739-d295a0d4e888Symplectic Elements at OxfordBioMed Central2018Kim, YLopez-Camacho, CNettleship, JRahman, NHill, MSilva-Reyes, LOrtiz-Martinez, GFigueroa-Aguilar, GMar, MVivanco-Cid, HRollier, CZitzmann, NViveros-Sandoval, MOwens, RReyes-Sandoval, A<strong>Background</strong>: Zika virus (ZIKV) has become a global threat with immediate need for accurate diagnostics, efficacious vaccines and therapeutics. Several ZIKV envelope (Env)-based vaccines have been developed recently. However, many commercially available ZIKV Env are based on the African lineage and produced in insect cells. Here, we sought to produce Asian-lineage ZIKV Env in mammalian cells for research and clinical applications. <strong>Methods</strong>: We designed various gene expression constructs to optimize the production of ZIKV using prM-Env and full or C-terminal truncations of Env; with or without a rat CD4 fusion partner to allow large-scale production of soluble protein in mammalian HEK293 cells. Protein expression was verified by mass spectrometry and western-blot with a pan-flavivirus antibody, a ZIKV Env monoclonal antibody and with immune sera from adenoviral (ChAdOx1) ZIKV Env-vaccinated mice. The resulting Env-CD4 was used as a coating reagent for immunoassay (ELISA) using both mouse and human seropositive sera. <strong>Results</strong>: Replacement of the C-terminus transmembrane Env domain by a rat CD4 and addition of prM supported optimal expression and secretion of Env. Binding between the antigens and the antibodies was similar to binding when using commercially available ZIKV Env reagents. Furthermore, antibodies from ZIKV patients bound ZIKV Env-CD4 in ELISA assays, whereas sera from healthy blood donors yielded minimal OD background. The serological outcomes of this assay correlated also with ZIKV neutralisation capacity in vitro. <strong>Conclusions</strong>: Results obtained from this study indicate the potential of the Asian-lineage Zika Env-CD4 and Env proteins in ELISA assays to monitor humoral immune responses in upcoming clinical trials as well as a sero-diagnostic tool in ZIKV infection.
spellingShingle Kim, Y
Lopez-Camacho, C
Nettleship, J
Rahman, N
Hill, M
Silva-Reyes, L
Ortiz-Martinez, G
Figueroa-Aguilar, G
Mar, M
Vivanco-Cid, H
Rollier, C
Zitzmann, N
Viveros-Sandoval, M
Owens, R
Reyes-Sandoval, A
Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_full Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_fullStr Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_full_unstemmed Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_short Optimization of Zika virus envelope protein production for ELISA and correlation of antibody titers with virus neutralization in Mexican patients from an arbovirus endemic region
title_sort optimization of zika virus envelope protein production for elisa and correlation of antibody titers with virus neutralization in mexican patients from an arbovirus endemic region
work_keys_str_mv AT kimy optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT lopezcamachoc optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT nettleshipj optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT rahmann optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT hillm optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT silvareyesl optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT ortizmartinezg optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT figueroaaguilarg optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT marm optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT vivancocidh optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT rollierc optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT zitzmannn optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT viverossandovalm optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT owensr optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion
AT reyessandovala optimizationofzikavirusenvelopeproteinproductionforelisaandcorrelationofantibodytiterswithvirusneutralizationinmexicanpatientsfromanarbovirusendemicregion